...
机译:使用inotuzumab ozogamicin单疗法治疗反复耐火性儿科预b急性淋巴细胞白血病,导致CD22抗原表达损失作为治疗抵抗机制
Department of Pediatrics Division of Pediatric Hematology-Oncology University of California San;
Department of Pediatrics Division of Pediatric Hematology-Oncology University of California San;
Department of Pediatrics Division of Pediatric Hematology-Oncology University of California San;
Department of Pediatrics Division of Pediatric Hematology-Oncology University of California San;
pre-B acute lymphoblastic leukemia; relapse; immunotherapy; inotuzumab ozogamicin; drug resistance;
机译:使用inotuzumab ozogamicin单疗法治疗反复耐火性儿科预b急性淋巴细胞白血病,导致CD22抗原表达损失作为治疗抵抗机制
机译:Inotuzumab ozogamicin作为复发B细胞急性淋巴细胞白血病的救生疗法,仅对CD22的循环爆炸进行了非常暗淡的CD22:一个案例报告
机译:伊诺单抗ozogamicin:一种CD22 mAb-药物偶联物,用于成人复发或难治性B细胞前体急性淋巴细胞白血病
机译:基于MeSH术语的microRNA调节小儿急性淋巴细胞白血病对糖皮质激素抵抗的语义分析
机译:小儿急性淋巴细胞白血病中糖皮质激素抵抗的机制。
机译:伊诺单抗ozogamicin:一种CD22 mAb-药物偶联物用于成人复发或难治性B细胞前体急性淋巴细胞白血病
机译:Inotuzumab ozogamicin用于在Ino-Vate试验中复发/难治性急性淋巴细胞白血病:CD22药效学,疗效和基线CD22的安全性